profit from every $100 of sales.
$0$100
Alkermes
$47.89+3.06% today
+41.6% in 1 year
1-year low $27.201-year high $55.22
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2020 to 2025.
0%20% a year
You pay $33.30 for every $1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Alkermes sold, what it kept, and what it did with the cash.
Sales went from $1.11 billion in 2022 to $1.48 billion in 2025, with $242 million of profit last year.
SalesProfit
Alkermes vs. similar companies
Alkermes grows in the middle of these 5 and is priced in the middle for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Alkermes | 33.3× · Expensive | ||
 Merck KGaA | 25.3× · Fair price | ||
 Takeda Pharmaceutical | 98.8× · Very expensive | ||
 Galderma Group | 89.1× · Very expensive | ||
 Teva Pharmaceutical Industries | 35.8× · Expensive |
AI analysis
An AI analyst reads Alkermes's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 1,039 | 1,174 | 1,112 | 1,663 | 1,558 | 1,476 | |
| 860 | 976 | 894 | 1,410 | 1,312 | 1,279 | |
| -112 | 98 | -6 | 414 | 421 | 254 | |
| -6 | 178 | 60 | 519 | 495 | 331 | |
| -111 | -48 | -158 | 356 | 367 | 242 | |
| -0.70 | -0.29 | -0.97 | 2.10 | 2.17 | 1.43 | |
| 82.8% | 83.2% | 80.4% | 84.8% | 84.2% | 86.7% | |
| -10.8% | 8.3% | -0.5% | 24.9% | 27.0% | 17.2% | |
| -10.7% | -4.1% | -14.2% | 21.4% | 23.6% | 16.4% |
Balance sheet
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 1,950 | 2,024 | 1,964 | 2,136 | 2,056 | 2,487 |
| Cash | 273 | 338 | 292 | 457 | 291 | 389 |
| Total debt | 410 | 416 | 379 | 372 | 76 | 70 |
| Total liabilities | 883 | 912 | 920 | 934 | 591 | 668 |
| 1,067 | 1,113 | 1,044 | 1,203 | 1,465 | 1,819 | |
| 159 | 165 | 164 | 170 | 169 | 169 | |
| -4.7% | 5.1% | -1.0% | 22.3% | 23.9% | 12.7% | |
| -10.4% | -4.3% | -15.2% | 29.6% | 25.1% | 13.3% |
Cash flow
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 83 | 102 | 21 | 401 | 439 | 521 | |
| 42 | 28 | 38 | 48 | 33 | 40 | |
| 41 | 74 | -17 | 353 | 406 | 480 | |
| Dividends paid | – | – | – | – | – | – |
| – | – | 0 | 0 | 200 | 0 | |
| 90 | 88 | 94 | 101 | 97 | 99 |
Valuation
- 33.3×
- –
- –
- 4.2×
- 5.5×
- 16.8×
- 23.4×
- 6.0%
- 3.0%
- 0.0%
Profitability
- 86.7%
- 17.2%
- 16.4%
- 17.7%
- 13.0%
- 14.8%
- 8.8%
- 3.6%
- 5.2%
- 22.8%
Growth
- +7.3%
- –
- +18.4%
- –
- +1.0%
Financial health
- -1.0×
- 0.04
- 37.1%
- 24.7×
- 3.55
- 1.70
- 0.37
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 18%of 958
Top 29%of 889
Bottom 38%of 601
Bottom 38%of 890
Top 17%of 987
What analysts expect
- Average price target
- $44.00
- Range
- $43.00 – $45.00
- 2 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 5, 2026 | -0.40 | -0.57 | +29.8% |
| Feb 25, 2026 | 0.34 | 0.43 | −20.9% |
| Oct 28, 2025 | 0.49 | 0.42 | +16.7% |
| Jul 29, 2025 | 0.52 | 0.41 | +26.8% |
| May 1, 2025 | 0.13 | 0.25 | −48.9% |
| Feb 12, 2025 | 1.04 | 0.81 | +28.4% |
| Oct 24, 2024 | 0.72 | 0.74 | −2.7% |
| Jul 24, 2024 | 0.70 | 0.70 | +0.0% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
4/7Passes 4 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
65Pass
Benjamin Graham
38No pass
Philip Fisher
58No pass
Peter Lynch
67Pass
Joel Greenblatt
20No pass
Charlie Munger
63Pass
Terry Smith
60Pass
Questions about Alkermes
Is Alkermes a good stock to buy?
A solid business, but the price is high. 4 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Alkermes AI analysis
What does Alkermes do?
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It is in Drug Manufacturers - Specialty & Generic, based in Dublin, Ireland, with 2,050 employees.
Does Alkermes pay a dividend?
No. Alkermes does not pay a dividend at the moment.
Is Alkermes stock halal?
Yes. Alkermes passes our halal screen: its business is permitted and its debt is 0.9% of its market value, under the 30% limit. How we check
How has Alkermes stock done over the past year?
Up 41.6% over the past twelve months, to $47.89. It traded between $27.20 and $55.22 and is 13.3% below its high.
Who are Alkermes's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Alkermes's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.